Objectives: given the scarcity of data regarding prevalence of various infectious diseases in 14 Latin-American countries, our study aims to assess the burden of T.cruzi, S.stercoralis, HIV and 15 viral hepatitis in Latin-American migrants, with a focus on Bolivian migrants. 16 Methods: we performed a retrospective observational study of 565 screening evaluations on 17 adults (≥ 18 years) carried out at our referral International Healthcare service in Barcelona. We 18 reviewed structured clinical records and microbiological results of patients attended between 19 February 2012 and April 2015. 20 Results: the median 35 years old and 74% were women. Bolivian origin accounted for 87% of 21 the screened population. We found a 48% prevalence of T.cruzi, 16% of S.stercoralis, 0.2% of 22 HIV, 92% of HAV, 0.2% HBV and 0.2% HCV. 31 Chagas disease) in people from Latin America; especially from Bolivia. In recent years screening 32 recommendations for Strongyloides stercoralis in this population was proven necessary. 33 Current recommendations regarding systematic screening for hepatitis B establish the 34 relevance of screening based on the probability of the disease in the 2% population of origin. 35 Since there are no reliable and up to date data regarding prevalence of hepatitis B virus in 36 Bolivia, we aimed to analyze data available for migrants from Bolivia in Spain. 37 Our results support the importance of screening for T. cruzi and S.stercoralis in patients from 38 Bolivia. However, our data show a much lower prevalence of this hepatitis B virus (0.2%) than 39 the 2% threshold that would justify systematic screening, so we question the relevance of 40 screening for hepatitis B virus in this population in the absence of other risk factors. 41
23
Conclusions: these results support the relevance of the screening of T. cruzi and S. stercoralis 24 in Bolivian migrants, but challenge the pertinence of systematic screening of HBV in this 25 population.
26
Author summary 27 In response to the challenge of detecting diseases not previously present in host countries, 28 screening programs have been implemented for migrants based on the probability of having 29 certain diseases depending on their country of origin and / or migratory route. This increased 30 risk is very clearly established in some cases such as Trypanosoma cruzi infection (the cause of Introduction 42
The increase in global migratory movements in recent decades implies new challenges for 43 health professionals and policy makers, especially regarding the need to diagnose and treat 44 previously non-endemic pathologies in the host countries. One of the diseases that best 45 illustrates this challenge is Chagas disease, caused by chronic infection by Trypanosoma cruzi It is estimated that 6-7 million people worldwide are infected with T.cruzi, mainly in Latin 48 America (LA), where it causes more than 10000 deaths per year (1) . The first reports of Chagas 49 disease in Europe were published in the early 1980s, with a marked increase around 2000, 50 along with the rising flow of migrants from LA to Europe(2-4). From 2007 onwards, a number 51 of initiatives both at national and international levels have been implemented in order to 52 increase awareness and provide better care to potentially affected populations (5). These aim 53 for better control vertical transmission (congenital, from mother to fetus)(6) and transmission 54 by infected blood and organ donors (7, 8) . Such initiatives include screening programs, which 55 are often the first contact of the migrant with the health system in host countries. Thus, they 56 represent an opportunity for a thorough medical examination and complementary tests. The 57 indication of performing these diagnostic tests derives from the estimated prevalence for each 58 risk group, using the country of origin in the absence of other known risk factors (9,10).
59
The relevance of conducting Chagas disease screening in Latin American migrants is based on 60 epidemiological data from the countries of origin as well as data from recipient countries:
61
WHO estimates a global prevalence of 1% in LA countries (11) positive HAV was significantly more frequent among individuals who were also positive for 202 T.cruzi, with an overall prevalence of 92%. (Table 3) 203 204
Hepatitis B virus.
A serologic test for HBV was performed in 88% (495) of the study population.
205
However, there was insufficient information for HBV classification on 141 individuals (28%).
206
Among those with a complete serology, there was a 7% prevalence of positive serology for 207 HBV (either by chronic or immune by past infection) -see obtained in 71% of the study population, with an overall prevalence of 16%. This prevalence of Strongyloides stercoralis infection was significantly higher in patients who were also positive 233 for T. cruzi (Table 3) .
234
Discussion 235 The aim of this study was to describe the prevalence of different infectious diseases in Bolivian 236 and other Latin-American migrants attending a referral International Health service in order to 237 establish more accurate screening protocols according to international recommendations.
238
First we should acknowledge that the vast majority of the screened individuals were from 239 Bolivia, and coming from several areas with a high migratory tradition (52). This limits the 240 generalization of the results to the Latin American community as a whole, but provides with a 241 robust source of information about the Bolivian community in our context. Hence, most of our 242 analysis will apply only to Bolivian migrants.
243
Another relevant finding is a prevalence for T. cruzi infection as high as 48% of the screened 244 population. This is probably due to various reasons. First, the majority of the screened 245 population was from highly endemic areas in Bolivia (with an expected prevalence of 18%)(12).
246
Secondly, some patients already know about their diagnosis before coming to our clinic. 
